a Evaluation of the percentages of human CD45+ TILs present in MC1 PDX tumors engrafted in hNSG mice and collected from animals treated with either vehicle control or anti-PD-1 antibody. The values represent the mean ± SEM (n = 8). b Schematic representation of the method used to determine the cytotoxic activity of TILs by measuring the levels of the lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon TIL-induced tumor cell lysis. TILs were isolated from MC1 PDX tumors engrafted in hNSG mice and treated with either vehicle or anti-PD1 antibody that were cocultured with disaggregated MC1 tumor cells obtained from the corresponding PDX grown in nonhumanized NSG mice. (PPTX 131 kb
Figure S1. Schematic representation of the therapeutic strategy. Figure S2. Schematic representation...
Additional file 8: Figure S8. PKP3/PD-L1 axis inhibition enhances the efficacy of anti-PD-1 therapy....
Figure S2. Gating strategy for flow cytometry analysis of primary AML burden. A representative flow ...
Effects of the anti-CTLA-4 immune checkpoint inhibitor antibody ipilimumab against MC1 PDXs implante...
IHC analysis of human CD4-, CD3-, CD8-, CD20-, CD68-, CD4-, and CD8-positive cells present in BCM-21...
Representative figure showing the results of flow cytometric analysis of human cells collected from ...
Table S1. Experimental details and timeline for tumor growth studies in BRGS and hu-CB-BRGS mice. (D...
Table S1 Analysis of HLA type in PDX BCM-2147/-4913 and CD34+ HSCs. HLA typing was performed by usin...
Histology analysis of extra MFP tumor developed in later stage in a mouse treated with MEDI3039. (A)...
Figure S3. In vivo efficacy profile of TEG001 in PD-X model of primary blast in NSG-SGM3 mice. (A) S...
Figure S6. Mouse PD1-Fc-OX40L efficacy Âą CD4/CD8 depletion in CT26 tumor model and schematics of tu...
Figure S1. Murine and human ANXA2 protein sequences. Brackets note differences. Figure S2. Sequentia...
Figure S1. PD-1 expression on CD4+ and CD8+ T-cells can increase with the addition of αCSF-1R to GVA...
Table S1. List of flow cytometry antibodies used for analysis of murine immune cell populations. Tab...
Figure S6. Biodistribution analysis of anti-cath-D F1 and E2 human antibodies. Nude mice bearing sub...
Figure S1. Schematic representation of the therapeutic strategy. Figure S2. Schematic representation...
Additional file 8: Figure S8. PKP3/PD-L1 axis inhibition enhances the efficacy of anti-PD-1 therapy....
Figure S2. Gating strategy for flow cytometry analysis of primary AML burden. A representative flow ...
Effects of the anti-CTLA-4 immune checkpoint inhibitor antibody ipilimumab against MC1 PDXs implante...
IHC analysis of human CD4-, CD3-, CD8-, CD20-, CD68-, CD4-, and CD8-positive cells present in BCM-21...
Representative figure showing the results of flow cytometric analysis of human cells collected from ...
Table S1. Experimental details and timeline for tumor growth studies in BRGS and hu-CB-BRGS mice. (D...
Table S1 Analysis of HLA type in PDX BCM-2147/-4913 and CD34+ HSCs. HLA typing was performed by usin...
Histology analysis of extra MFP tumor developed in later stage in a mouse treated with MEDI3039. (A)...
Figure S3. In vivo efficacy profile of TEG001 in PD-X model of primary blast in NSG-SGM3 mice. (A) S...
Figure S6. Mouse PD1-Fc-OX40L efficacy Âą CD4/CD8 depletion in CT26 tumor model and schematics of tu...
Figure S1. Murine and human ANXA2 protein sequences. Brackets note differences. Figure S2. Sequentia...
Figure S1. PD-1 expression on CD4+ and CD8+ T-cells can increase with the addition of αCSF-1R to GVA...
Table S1. List of flow cytometry antibodies used for analysis of murine immune cell populations. Tab...
Figure S6. Biodistribution analysis of anti-cath-D F1 and E2 human antibodies. Nude mice bearing sub...
Figure S1. Schematic representation of the therapeutic strategy. Figure S2. Schematic representation...
Additional file 8: Figure S8. PKP3/PD-L1 axis inhibition enhances the efficacy of anti-PD-1 therapy....
Figure S2. Gating strategy for flow cytometry analysis of primary AML burden. A representative flow ...